Fig. 4From: Immune checkpoint inhibitors for multiple myeloma immunotherapyRuxolitinib can block PD-L1 expression, thus enhancing the anti-MM effect of T cells.So Altering the expression of immune checkpoints may provide a new idea for immunotherapy of MMBack to article page